When most people hear about GLP-1 medications like semaglutide or tirzepatide, they immediately think about diabetes or weight loss. In this video, I share a different perspective: the potential role of GLP-1 receptor agonists at microdoses in conditions where chronic inflammation is central to disease progression.

We know that inflammation underlies many disorders — from autoimmune disease to neurodegenerative conditions. While there are currently no large-scale clinical studies on microdosing GLP-1s for these indications, there are intriguing reasons to consider their potential. GLP-1 medications have been shown to influence metabolic pathways, reduce systemic inflammation, and even demonstrate neuroprotective properties in some research settings.

That’s why I’m interested in whether carefully supervised, very low doses of these drugs might offer benefits in conditions such as: Autoimmune disease Chronic pain syndromes PCOS (Polycystic Ovary Syndrome)

Mood and mental health issues Alzheimer’s disease and cognitive decline Cardiovascular and heart disease

I want to be clear: this is an area of clinical curiosity, not established science. We don’t yet have the studies to guide us. But under the right medical supervision, there may be a safe way to explore whether microdosing could help patients who struggle with inflammation-driven diseases and have not found relief elsewhere.

At Complete Midlife Wellness Center, my team and I welcome patients who are interested in innovative, science-informed approaches to health. If this conversation resonates with you, I’d be glad to explore whether GLP-1 microdosing might be an option for your unique situation.

👉 Learn more or schedule a consultation: CompleteMidlifeWellnessCenter.com